The total amount of venture capital investing in genomics firms rose to $392 million in 2012, up from $332 million in 2011, according to the blog Seqonomics.

The amount is the most in VC funding to genomics firms that Seqonomics has found, going back to 2006. However, rather than there being more VC deals in 2012, Sanger Institute postdoctoral fellow Art Wuster says that the higher amount in total investments results from a higher average for each investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Moving Money Around

The Cost Burden

R&D Dollars

That Tiny Little Bit?

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.